PharmaEngine

NEW DRUGS FOR THE TREATMENT OF CANCER

PharmaEngine
We Race With You

CANCER TREATMENT PRODUCTS

ONIVYDE
A Revolutionary Durg

DISCOVER ONIVYDE

NEW CONCEPTS FOR RADIOTHERAPY

Groundbreaking
Cancer Treatment

DISCOVER PEP503

History<br>
&<br>
Milestones<br> — History
&
Milestones

Onivyde

PharmaEngine, Inc. Announces First Results for PEP503(NBTXR3) in Rectal Cancer Study at ASCO-GI 2021

PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor

PharmaEngine Starts the PEP503 (NBTXR3) Phase 2 Study in Locally Advanced or Unresectable Rectal Cancer

Events & Presentations

Go To Top